SEC filings and other documents

Q2 2026 featured sharp cost cuts, a net loss, and a cash runway projected into mid-2027.

All proposals, including director elections and equity plan amendment, were approved.

Q1 2026 featured lower expenses, a $4.1M net loss, and extended cash runway into mid-2027.

Returned to profitability in 2025 with a strengthened cash position and reduced expenses.

Q3 2025 featured FDA Priority Review for tab-cel, major cost reductions, and a pending $40M milestone.

Q2 2025 marked a return to profitability, reduced expenses, and a key regulatory milestone.

All proposals passed, including director elections and auditor ratification, with no questions raised.

Returned to profitability in Q1 2025 as cost cuts and new funding extended cash runway.

EBVALLO focus intensifies as Atara restructures, cuts losses, and seeks strategic alternatives.

Mount Todd targets a smaller, higher-grade gold project and seeks a value-creating partnership.

Tab-cel nears U.S. launch; allogeneic CAR-T platform advances with key data expected in 2025.

Advancing allogeneic CAR T therapies with pivotal data expected and funding secured through 2027.

Revenue surged and losses narrowed as Atara advances key cell therapy programs.

Allogeneic CAR-T platform advances with Tab-cel U.S. review and robust pipeline in oncology and autoimmunity.

Off-the-shelf T-cell therapies advance toward US approval, targeting cancer and autoimmune diseases.

Allogeneic T-cell platform advances with key clinical milestones and strong financial runway.

First-in-class allogeneic T-cell therapy advances toward U.S. approval and clinical expansion.

Q2 revenue surged, losses narrowed, and tab-cel BLA advanced with milestone payments.

Allogeneic T-cell therapies advance in oncology and autoimmune disease, with US launch set for 2025.